|
Variable
|
Group TMP (N = 22)
|
Group TMN (N = 20)
|
P value
|
|---|
|
Age, years
|
52.0 (34.8, 58.0)
|
54.5 (29.0, 63.8)
|
0.734
|
|
Male sex, no. (%)
|
14 (63.6%)
|
13 (65.0%)
|
1.0
|
|
Anti-IFN-γ antibody titer (ng/ml)
|
926.31 (760.02, 2103.20)
|
332.40 (243.51,491.89)
|
<0.001
|
|
Time from symptom onset to diagnosis
|
149.5 (57.2, 272.3)
|
98.5 (22.3154.5)
|
0.107
|
|
Coexisting respiratory disease, no. (%)
|
3 (13.6%)
|
10 (50.0%)
|
0.019
|
|
Bronchiolitis
|
0
|
4 (20.0%)
|
0.043
|
|
COPD
|
2 (9.1%)
|
4 (20.0%)
|
0.400
|
|
COPD with bronchiectasis
|
0
|
2 (10.0%)
|
0.221
|
|
Asthma
|
1 (4.5%)
|
0
|
0.476
|
|
Extrapulmonary organ involvement, no. (%)
|
18 (81.8%)
|
11 (55.0%)
|
0.096
|
|
Skin
|
10 (45.5%)
|
3 (15.0%)
|
0.047
|
|
Lymph node
|
18 (81.8%)
|
11 (55.0%)
|
0.096
|
|
Liver
|
2 (9.1%)
|
1 (5.0%)
|
1.000
|
|
Spleen
|
2 (9.1%)
|
0
|
0.489
|
|
Bone
|
9 (40.9%)
|
1 (5.0%)
|
0.010
|
|
Symptoms, no. (%)
|
|
Fever
|
12 (54.5%)
|
6 (30.0%)
|
0.131
|
|
Cough
|
17 (77.3%)
|
17 (85.0%)
|
0.700
|
|
Sputum production
|
14 (63.6%)
|
15 (75.0%)
|
0.514
|
|
Hemoptysis
|
4 (18.2%)
|
3 (15.0%)
|
1.0
|
|
Dyspnea
|
6 (27.3%)
|
3 (15%)
|
0.460
|
|
Chest pain
|
9 (40.9%)
|
6 (30.0%)
|
0.531
|
|
Osteodynia/Arthralgia
|
7 (31.8%)
|
3 (15.0%)
|
0.284
|
|
Wasting
|
13 (59.0%)
|
10 (50.0%)
|
0.757
|
|
Moist rales
|
6 (27.3%)
|
8 (40.0%)
|
0.515
|
|
Pleural effusion
|
13 (59.1%)
|
3 (15.0%)
|
0.005
|
|
Co-infection, no. (%)
|
12 (55.0%)
|
4 (20.0%)
|
0.029
|
|
Outcome, no. (%)a
|
|
Cured
|
0
|
2 (10.0%)
|
–
|
|
Improved
|
2 (9.1%)
|
4 (20.0%)
|
–
|
|
Ineffective
|
6 (27.3%)
|
0
|
–
|
|
Recurrence
|
1 (4.5%)
|
0
|
–
|
|
Death
|
3 (13.6%)
|
0
|
–
|
- aData were available for 12 patients in group TMP and 6 patients in group TMN during the longitudinal follow-up
- Group TMP = anti-IFN-γ autoantibody-positive group
- Group TMN = anti-IFN-γ autoantibody-negative group
- COPD Chronic obstructive pulmonary disease
- NTM Nontuberculous Mycobacterium
